Tasquinimod improves radiographic PFS in mCRPC

Tasquinimod improves radiographic PFS in mCRPC
(HealthDay)—For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study published online June 13 in the Journal of Clinical Oncology.

Cora Sternberg, M.D., from the San Camillo Forlanini Hospital in Rome, and colleagues conducted a phase III trial involving men with chemotherapy-naive mCRPC and evidence of . A total of 1,245 patients were randomized to tasquinimod once per day (832 men) or placebo (413 men) at 241 sites in 37 countries. The primary end point was rPFS per Prostate Cancer Working Group 2 criteria and RECIST 1.1.

The researchers found that the estimated median rPFS by central review was 7.0 and 4.4 months with tasquinimod and placebo, respectively (hazard ratio, 0.64; 95 percent confidence interval, 0.54 to 0.75; P < 0.001). The median overall survival (OS) was 21.3 and 24.0 months with tasquinimod and placebo, respectively (hazard ratio, 1.10; 95 percent confidence interval, 0.94 to 1.28; P = 0.25). More frequent grade ≥3 adverse events were seen with tasquinimod (42.8 versus 33.6 percent), most commonly anemia, fatigue, and cancer pain.

"In chemotherapy-naive with mCRPC, tasquinimod significantly improved rPFS compared with placebo," the authors write. "However, no OS benefit was observed."

Several authors disclosed financial ties to the biopharmaceutical industry; the study was funded by Active Biotech, the manufacturer of tasquinimod.


Explore further

Oral drug may improve survival in men with metastatic prostate cancer

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Clinical Oncology

Copyright © 2016 HealthDay. All rights reserved.

Citation: Tasquinimod improves radiographic PFS in mCRPC (2016, June 16) retrieved 19 June 2019 from https://medicalxpress.com/news/2016-06-tasquinimod-radiographic-pfs-mcrpc.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more